Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?

Shares of Hikma Pharmaceuticals PLC (LON:HIK) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,921.22 ($24.37) and traded as high as GBX 1,944 ($24.66). Hikma Pharmaceuticals shares last traded at GBX 1,938 ($24.59), with a volume of 178,291 shares changing hands.

Wall Street Analyst Weigh In

Separately, Berenberg Bank upgraded Hikma Pharmaceuticals to a “buy” rating and raised their price objective for the stock from GBX 2,100 ($26.64) to GBX 2,400 ($30.45) in a report on Monday, September 2nd.

Hikma Pharmaceuticals Trading Down 1.2 %

The stock has a market capitalization of £4.25 billion, a PE ratio of 2,981.54, a PEG ratio of 2.38 and a beta of 0.41. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.48. The business’s 50-day moving average is GBX 1,907.09 and its two-hundred day moving average is GBX 1,921.22.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.